Genelux Corporation Common Stock (GNLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $84.38M
Last updated: Nov 17, 2026 at 11:05 AM ET
Genelux Corporation Common Stock (GNLX) Competitors
The companies most similar to Genelux Corporation Common Stock are MacroGenics (MGNX), Gossamer Bio (GOSS) and enGene Therapeutics (ENGN). By market cap, Genelux Corporation Common Stock ranks 8th of the 13 companies on this page; enGene Therapeutics (ENGN) is the largest at $161.51M.
Peer Comparison
GNLX's revenue growth of -95.3% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Genelux Corporation Common Stock (GNLX) | $84.38M | N/A | N/A | 0.0% | N/A | -95.3% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Gossamer Bio Inc (GOSS) | $67.10M | N/A | 0.9x | -159.5% | 147.4% | 189.1% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Voyager Therapeutics Inc (VYGR) | $107.66M | N/A | 4.0x | 0.0% | N/A | -70.0% | 0.00% |
| Champions Oncology Inc (CSBR) | $65.49M | N/A | 1.0x | -1.9% | N/A | 8.8% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Oncolytics Biotech Inc (ONCY) | $48.51M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Tiziana Life Sciences Ltd (TLSA) | $72.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $96.84M | N/A | 1.3x | 0.0% | -74.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Genelux Corporation Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Gossamer Bio Inc (GOSS) | Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing... | GOSS competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Voyager Therapeutics Inc (VYGR) | Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. | VYGR competitors |
| Champions Oncology Inc (CSBR) | Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. | CSBR competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Oncolytics Biotech Inc (ONCY) | Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. | ONCY competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Tiziana Life Sciences Ltd (TLSA) | Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat... |
Frequently Asked Questions About GNLX
Who are Genelux Corporation Common Stock's main competitors?
The companies most similar to Genelux Corporation Common Stock include MacroGenics (MGNX), Gossamer Bio (GOSS), enGene Therapeutics (ENGN), Cellectis SA (CLLS) and Voyager Therapeutics (VYGR), listed from the closest match.
Who is Genelux Corporation Common Stock's biggest competitor?
enGene Therapeutics (ENGN) is the largest of the similar companies at $161.51M; MacroGenics (MGNX) is the closest match by business profile, size, sector and industry.
How does GNLX stock compare with its competitors?
GNLX's net margin is 0.0% against a peer median of 0.0%.
Which of Genelux Corporation Common Stock's competitors pays a higher dividend?
Genelux Corporation Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Genelux Corporation Common Stock bigger than its competitors?
No. Genelux Corporation Common Stock is 8th by market cap among the 13 companies on this page; the largest is enGene Therapeutics (ENGN) at $161.51M.
GNLX pages: Overview, Earnings, Forecast, Financials, Competitors